How do arterial and venous intracranial hemorrhages differ in presentation, imaging findings, and management?

Arterial vs Venous Intracranial Hemorrhage: Key Distinctions

Arterial and venous intracranial hemorrhages differ fundamentally in their underlying vascular pathology, imaging patterns, and management—most critically, venous hemorrhage (from cerebral venous thrombosis) requires anticoagulation despite the presence of blood, while arterial hemorrhage typically contraindicates it.

Underlying Pathophysiology

Arterial hemorrhage results from:

• Hypertensive vessel rupture (most common)
• Ruptured aneurysms
• Arteriovenous malformations (AVMs)
• Cerebral amyloid angiopathy
• Arterial infarction with hemorrhagic transformation

Venous hemorrhage occurs from:

• Cerebral venous sinus thrombosis (CVST) causing venous infarction with secondary hemorrhage
• Thrombosis leads to venous hypertension, blood-brain barrier breakdown, and hemorrhagic transformation 1

Clinical Presentation Patterns

Location Clues

Arterial hemorrhages typically occur in:

• Deep structures (basal ganglia, thalamus) in hypertensive hemorrhage
• Lobar locations in younger patients or those with CAA 2
• Subarachnoid space with aneurysmal rupture

Venous hemorrhages show distinctive patterns:

• Hemorrhagic lesions that cross arterial territories (key distinguishing feature) 3
• Parasagittal or cortical locations
• Bilateral thalamic involvement
• Unilateral thalamic hemorrhage with intraventricular extension 3

Age and Risk Factors

• Younger age (<45-70 years) without hypertension strongly suggests underlying vascular malformation requiring angiography 2, 4
• Female sex predicts higher likelihood of macrovascular cause 2
• Presence of small vessel disease on imaging suggests lower likelihood of macrovascular etiology 2

Imaging Findings

CT Characteristics

Arterial hemorrhage:

• Hyperdense acute blood in typical vascular territory distributions
• May show "spot sign" indicating active extravasation
• Intraventricular extension common with deep hemorrhages

Venous hemorrhage:

• Hemorrhage crossing arterial boundaries (critical finding) 5
• "Empty delta sign" on contrast CT (hypodense thrombus in enhanced sinus) 1
• "Hyperdense vein sign" on non-contrast CT 1

MRI/MRA/MRV Superiority

MRI is the technique of choice for distinguishing arterial from venous etiology 5, 6:

For venous thrombosis detection 1:

• Absence of normal flow void in dural sinus
• T2 hypointensity suggesting thrombus in first week
• T1/T2 hyperintensity after second week (methemoglobin)
• Susceptibility-weighted imaging shows blooming artifact
• MR venography confirms absent venous flow

For arterial causes 2:

• Blood-sensitive T2* sequences detect microbleeds and cortical superficial siderosis (suggests CAA)
• Contrast-enhanced T1 excludes neoplasm
• MRA/CTA detects aneurysms, AVMs, dural arteriovenous fistulae

Critical Imaging Pitfall

Flow-related artifacts on MR venography can mimic thrombosis 3. Always correlate venographic findings with parenchymal imaging patterns to avoid overdiagnosis of CVST.

Diagnostic Algorithm

When to Pursue Vascular Imaging 2:

1. Age <70 years with lobar hemorrhage
2. Age <45 years with deep/posterior fossa hemorrhage
3. Age 45-70 years with deep hemorrhage WITHOUT hypertension history
4. Female sex
5. Hemorrhage crossing arterial territories (suggests venous)

Imaging Sequence:

1. Non-contrast CT initially
2. CTA within 24 hours if high-risk features present
3. MRI/MRA/MRV at 46 days median (per DIAGRAM study) for comprehensive evaluation 2
4. Digital subtraction angiography if non-invasive imaging inconclusive

Management: The Critical Distinction

Arterial Hemorrhage Management 2:

Blood Pressure Control:

• Target SBP 130-150 mm Hg for mild-moderate hemorrhage with initial SBP 150-220 mm Hg
• Initiate within 2 hours, reach target within 1 hour
• Avoid SBP <130 mm Hg (potentially harmful)
• Ensure smooth, sustained control avoiding peaks and variability

Anticoagulation:

• Generally contraindicated acutely
• VTE prophylaxis timing controversial but mechanical prophylaxis (intermittent pneumatic compression) should start at admission 7
• Pharmacological VTE prophylaxis appears safe 24-48 hours after documented bleeding cessation 7

Venous Hemorrhage Management 1:

THE PARADIGM-SHIFTING PRINCIPLE: Intracranial hemorrhage from CVST is NOT a contraindication to anticoagulation 1

Anticoagulation Protocol:

• Initiate IV heparin or subcutaneous LMWH immediately upon CVST diagnosis
• Continue oral anticoagulation 3-12 months or lifelong depending on etiology
• Transient/reversible factors: 3-6 months
• High-risk inherited thrombophilia: lifelong

Escalation for deterioration:

• Consider endovascular therapy with/without mechanical thrombectomy
• Decompressive hemicraniectomy for severe mass effect (lifesaving)

Prognostic Implications

Arterial hemorrhage:

• Mortality/morbidity driven by hematoma volume, location, and expansion
• Intensive BP lowering may improve functional outcomes 2

Venous hemorrhage:

• Long-term outcomes determined by venous-related parenchymal injury, not hemorrhage volume alone 3
• Pattern-guided imaging interpretation critical for prognosis
• Anticoagulation prevents thrombus propagation and promotes recanalization 1

Common Pitfalls to Avoid

1. Assuming all intracranial hemorrhage contraindicates anticoagulation—this is false for CVST 1
2. Relying solely on CT without venous phase imaging when hemorrhage crosses arterial territories
3. Overdiagnosing CVST based on MRV artifacts without correlating parenchymal findings 3
4. Withholding angiography in young patients with "typical" hypertensive hemorrhage—26% have underlying vascular abnormalities 4
5. Targeting SBP <130 mm Hg in arterial ICH—this is potentially harmful 2